We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Bone Therapeutics Sa | LSE:0R55 | London | Ordinary Share | BE0974280126 | BONE THERAPEUTICS ORD SHS |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.845 | 3.75 | 3.94 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 316k | -2.04M | -0.0168 | -1.19 | 2.44M |
PRESS RELEASE – INSIDE INFORMATION
Following a post-hoc analysis of a Phase 3 trial demonstrating pain relief in patients with severe knee osteoarthritis, Biosenic applied for an international patent to support the newly focused indication of JTA-004.
Mont-Saint-Guibert, Belgium, January 23, 2024, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company focused on serious autoimmune and inflammatory diseases and cell therapy, today announces the filing of a U.S. patent for JTA-004, a viscosupplement in late-stage clinical development, following new evidence of its efficacy in a recently defined subtype of osteoarthritis (OA).
There are several types of OA. In 2022, outside investigators publishedi findings that defined three subtypes based on biomarkers – including a severe form marked by high levels of pain, of certain biomarkers and persistent and progressive inflammation. Using this new approach to stratifying disease, BioSenic commissioned a post hoc analysis of a phase 3 trial for JTA-004 that had showed inconclusive results for patients with knee OA. By instead focusing on patients in their study with the severe inflammatory subtype, the analysis detected pain-relieving efficacy superior to both placebo and the active comparator.
Given the promising new findings, BioSenic now intends to expand patent protection for "Hyaluronic acid-based compositions and related methods for use in the treatment of osteoarthritis in specifically selected subjects." The rights were initially acquired from Bone Therapeutics following a reverse merger with Medsenic SAS to form BioSenic. As BioSenic develops a new clinical plan, this position will support steps toward commercializing JTA-004 for patients experiencing severe pain from knee OA.
JTA-004 differs from other hyaluronic acid-based products for OA in its inclusion of clonidine, an alpha-2 adrenergic inhibitor, as an active pharmacological component. Its analgesic properties have been known for decades, and more recent data has demonstrated prolonged local anti-inflammatory activity, as well as a normalizing effect on cell differentiation of chondrocytes. New findings publishedii this month in Nature further connect chondrocytes to degeneration in knee OA, providing further potential explanation for JTA-004’s positive clinical results in reducing symptoms of pain and inflammation in severe cases.
Prof. François Rieger, PhD, Chairman and Chief Executive Officer of BioSenic said: "Given the exciting new findings in knee osteoarthritis, it is time to build on previous efforts to develop JTA-004 to control the most severe subtype of progressive knee osteoarthritis. As further clinical work is needed to fully establish the significant benefits expected from JTA-004, our IP position will provide significant protection as we explore partnerships to bring this important asset to a very large pharmacological market. We are dedicated to improving the lives of millions of patients continue to suffer from this often-debilitating disease.”
iAngelini F, et al. Ann Rheum Dis Feb 2022iiFu W, et al. Nature Jan 2024
About BioSenic
BioSenic is a biotech company specializing in the development of clinical assets issued from: (i) the arsenic trioxide (ATO) platform (with key target indications including Graft-versus-Host Disease (GvHD), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) and (ii), the development of innovative products to meet unmet needs in immune and autoimmune diseases. Following a reverse merger in October 2022, BioSenic combined its strategic positioning and key strengths to develop, separately and in combination, an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/oral ATO (OATO) with its innovative cell therapy platform and strong IP for tissue repair protection.
BioSenic is based in the Louvain-la-Neuve Science Park in Mont-Saint-Guibert, Belgium. Further information is available on the website at http://www.biosenic.com.
About BioSenic technology platforms
The company is currently focusing its present R&D and clinical activities on a selective, accelerated development of its autoimmune (ATO/OATO) platform.
For further information, please contact:
BioSenic SAFrançois Rieger, PhD, Chief Executive OfficerTel: +33 (0)671 73 31 59investorrelations@biosenic.com
International Media Enquiries:IB CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20 8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Investor Enquiries:Seitosei ● ActifinGhislaine GasparettoTel: +33 (0)1 56 88 11 22 ghislaine.gasparetto@seitosei-actifin.com
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the company or, as appropriate, the company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.
1 Year Bone Therapeutics Chart |
1 Month Bone Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions